Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-09-11 11:47:11 UTC |
---|
Update Date | 2021-09-26 23:06:32 UTC |
---|
HMDB ID | HMDB0253369 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | Icotinib |
---|
Description | Icotinib belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups. Icotinib is a strong basic compound (based on its pKa). Icotinib is approved for use as first-line monotherapy in patients with non-small-cell lung cancer with somatic EGFR mutations. Currently, it is solely approved and marketed in China. The phase IV ISAFE trial evaluated 5,549 patients and showed icotinib to have an overall response rate of 30% and an adverse event rate of 31.5%. The following trial was submitted in January, 2014 and was to begin recruitment in August, 2014. This compound has been identified in human blood as reported by (PMID: 31557052 ). Icotinib is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Icotinib is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | C#CC1=CC=CC(NC2=NC=NC3=CC4=C(OCCOCCOCCO4)C=C23)=C1 InChI=1S/C22H21N3O4/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20/h1,3-5,12-15H,6-11H2,(H,23,24,25) |
---|
Synonyms | Value | Source |
---|
BPI-2009H | ChEMBL | 4-((3-Ethynylphenyl)amino)-6,7-benzo-12-crown-4-quinazoline | MeSH |
|
---|
Chemical Formula | C22H21N3O4 |
---|
Average Molecular Weight | 391.427 |
---|
Monoisotopic Molecular Weight | 391.153206168 |
---|
IUPAC Name | N-(3-ethynylphenyl)-7H,8H,10H,11H,13H,14H-1,4,7,10-tetraoxacyclododeca[2,3-g]quinazolin-4-amine |
---|
Traditional Name | N-(3-ethynylphenyl)-7H,8H,10H,11H,13H,14H-1,4,7,10-tetraoxacyclododeca[2,3-g]quinazolin-4-amine |
---|
CAS Registry Number | Not Available |
---|
SMILES | C#CC1=CC=CC(NC2=NC=NC3=CC4=C(OCCOCCOCCO4)C=C23)=C1 |
---|
InChI Identifier | InChI=1S/C22H21N3O4/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20/h1,3-5,12-15H,6-11H2,(H,23,24,25) |
---|
InChI Key | QQLKULDARVNMAL-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Diazanaphthalenes |
---|
Sub Class | Benzodiazines |
---|
Direct Parent | Quinazolinamines |
---|
Alternative Parents | |
---|
Substituents | - Quinazolinamine
- Aniline or substituted anilines
- Alkyl aryl ether
- Aminopyrimidine
- Monocyclic benzene moiety
- Pyrimidine
- Benzenoid
- Imidolactam
- Heteroaromatic compound
- Dialkyl ether
- Ether
- Acetylide
- Secondary amine
- Oxacycle
- Azacycle
- Organonitrogen compound
- Amine
- Organooxygen compound
- Organic oxygen compound
- Hydrocarbon derivative
- Organopnictogen compound
- Organic nitrogen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Icotinib,1TMS,isomer #1 | C#CC1=CC=CC(N(C2=NC=NC3=CC4=C(C=C23)OCCOCCOCCO4)[Si](C)(C)C)=C1 | 3495.8 | Semi standard non polar | 33892256 | Icotinib,1TMS,isomer #1 | C#CC1=CC=CC(N(C2=NC=NC3=CC4=C(C=C23)OCCOCCOCCO4)[Si](C)(C)C)=C1 | 3225.2 | Standard non polar | 33892256 | Icotinib,1TMS,isomer #1 | C#CC1=CC=CC(N(C2=NC=NC3=CC4=C(C=C23)OCCOCCOCCO4)[Si](C)(C)C)=C1 | 5170.9 | Standard polar | 33892256 | Icotinib,1TBDMS,isomer #1 | C#CC1=CC=CC(N(C2=NC=NC3=CC4=C(C=C23)OCCOCCOCCO4)[Si](C)(C)C(C)(C)C)=C1 | 3700.0 | Semi standard non polar | 33892256 | Icotinib,1TBDMS,isomer #1 | C#CC1=CC=CC(N(C2=NC=NC3=CC4=C(C=C23)OCCOCCOCCO4)[Si](C)(C)C(C)(C)C)=C1 | 3429.3 | Standard non polar | 33892256 | Icotinib,1TBDMS,isomer #1 | C#CC1=CC=CC(N(C2=NC=NC3=CC4=C(C=C23)OCCOCCOCCO4)[Si](C)(C)C(C)(C)C)=C1 | 5224.1 | Standard polar | 33892256 |
| Show more...
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Icotinib GC-MS (Non-derivatized) - 70eV, Positive | splash10-029i-0296000000-91bcc78f973511977994 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Icotinib GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Icotinib 10V, Positive-QTOF | splash10-000x-1319000000-b7852e0d27d68d1e8625 | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Icotinib 20V, Positive-QTOF | splash10-01pp-1029000000-72202e24212d3888431d | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Icotinib 40V, Positive-QTOF | splash10-01vk-9480000000-ec18f935500546138b7a | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Icotinib 10V, Negative-QTOF | splash10-0006-0009000000-cd7c412b03e939edc63d | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Icotinib 20V, Negative-QTOF | splash10-0006-2129000000-df7742984b7ddc5aa621 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Icotinib 40V, Negative-QTOF | splash10-00g1-6193000000-8b873d67972a297b9083 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Icotinib 10V, Positive-QTOF | splash10-0006-0009000000-c406f51f24d1cf16240c | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Icotinib 20V, Positive-QTOF | splash10-0006-0009000000-c406f51f24d1cf16240c | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Icotinib 40V, Positive-QTOF | splash10-01bc-1797000000-dc418a8f79ec3e435ff5 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Icotinib 10V, Negative-QTOF | splash10-0006-0009000000-473c9abfcfb419a2363d | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Icotinib 20V, Negative-QTOF | splash10-0006-0009000000-bbc706598cfafa661b89 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Icotinib 40V, Negative-QTOF | splash10-01b9-0975000000-72e4247bb4d45c6ecafb | 2021-10-12 | Wishart Lab | View Spectrum |
| Show more...
---|
Biological Properties |
---|
Cellular Locations | Not Available |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Detected but not Quantified | Not Quantified | Not Specified | Not Specified | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB11737 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | Not Available |
---|
KEGG Compound ID | Not Available |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Icotinib |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 22024915 |
---|
PDB ID | Not Available |
---|
ChEBI ID | Not Available |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Barupal DK, Fiehn O: Generating the Blood Exposome Database Using a Comprehensive Text Mining and Database Fusion Approach. Environ Health Perspect. 2019 Sep;127(9):97008. doi: 10.1289/EHP4713. Epub 2019 Sep 26. [PubMed:31557052 ]
|
---|